MG
ANAB icon

Michael Gelband’s AnaptysBio ANAB Stock Holding History

Michael Gelband’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,260
Closed -$403K – 1543
2026
Q1 		$403K Sell
7,260
-76,053
-91% -$4.09M ﹤0.01% 1247
2025
Q4 		$4.04M Buy
83,313
+56,813
+214% +$2.21M 0.03% 556
2025
Q3 		$811K Buy
26,500
+2,744
+12% +$63K 0.01% 1031
2025
Q2 		$527K Buy
23,756
+1,812
+8% +$37.9K ﹤0.01% 1138
2025
Q1 		$408K Buy
+21,944
New +$366K ﹤0.01% 1157
2024
Q4 		– Sell
-12,284
Closed -$412K – 1486
2024
Q3 		$412K Sell
12,284
-128,215
-91% -$4.38M ﹤0.01% 1260
2024
Q2 		$3.52M Buy
+140,499
New +$3.27M 0.02% 562
2024
Q1 		– Sell
-24,672
Closed -$528K – 1467
2023
Q4 		$528K Sell
24,672
-15,867
-39% -$274K ﹤0.01% 1020
2023
Q3 		$728K Sell
40,539
-48,046
-54% -$917K 0.01% 1091
2023
Q2 		$1.8M Sell
88,585
-45,457
-34% -$922K 0.01% 854
2023
Q1 		$2.92M Buy
134,042
+38,784
+41% +$943K 0.02% 733
2022
Q4 		$2.95M Buy
95,258
+59,017
+163% +$1.67M 0.04% 506
2022
Q3 		$925K Sell
36,241
-71,383
-66% -$1.67M 0.01% 1141
2022
Q2 		$2.19M Buy
107,624
+30,178
+39% +$668K 0.03% 743
2022
Q1 		$1.92M Buy
+77,446
New +$2.34M 0.02% 801
2021
Q4 		– Sell
-7,599
Closed -$206K – 2136
2021
Q3 		$206K Sell
7,599
-26,080
-77% -$662K ﹤0.01% 1768
2021
Q2 		$873K Buy
+33,679
New +$807K 0.01% 1072
2020
Q4 		– Sell
-13,949
Closed -$206K – 1929
2020
Q3 		$206K Sell
13,949
-14,951
-52% -$270K ﹤0.01% 1462
2020
Q2 		$646K Buy
+28,900
New +$528K 0.02% 951

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Michael Gelband's ANAB Position: Q2 2026 in Review

Michael Gelband sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 7,260 shares — an estimated $403K sold.

Michael Gelband first reported a position in ANAB in Q2 2020 and held it in 19 quarters. The position peaked at $4.04M in Q4 2025. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Michael Gelband reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 7,260 AnaptysBio shares in Q2 2026, an estimated $403K.
  • Michael Gelband first reported a position in AnaptysBio in Q2 2020 and held it in 19 quarters.
  • Michael Gelband's AnaptysBio position peaked at $4.04M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.